Last reviewed · How we verify
NCT06955286
Study on the Incidence of Adrenal Insufficiency After Surgery in Primary Aldosteronism Patients Concurrent With or Without Autonomous Cortisol Secretion
trial testing complete ACTH stimulation test the day after surgery in Primary Aldosteronism in 200 participants. Currently enrolling.
31 December 2027
Quick facts
| Lead sponsor | Qifu Li |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 2 January 2025 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 December 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- complete ACTH stimulation test the day after surgery
Conditions studied
- Primary Aldosteronism — all drugs for Primary Aldosteronism →
- Autonomous Cortisol Secretion — all drugs for Autonomous Cortisol Secretion →
- Adrenal Insufficiency — all drugs for Adrenal Insufficiency →
Sponsor
Qifu Li — full company profile →
Who can join
Adults 18 to 70, any sex, with Primary Aldosteronism or Autonomous Cortisol Secretion. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the incidence of adrenal insufficiency after surgery in Primary aldosteronism (PA) patients concurrent with or without autonomous cortisol secretion (ACS).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06955286
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Primary Aldosteronism
Currently open trials in the same condition.
- NCT07298954 — Sequential Combined Versus Single-Strategy Adrenal Venous Sampling for Primary Aldosteronism(SCOPE) · NA · recruiting
- NCT07111351 — Multi-omics Studies of Primary Aldosteronism · recruiting
- NCT07027254 — PETAL Trial: Impact of Gallium-68 Pentixafor PET-CT on Surgical Outcomes in Primary Aldosteronism · NA · recruiting
- NCT06941116 — Steroids-Based Screening for Primary Aldosteronism · recruiting
- NCT06740838 — Overnight Dexamethasone in Primary Aldosteronism Screening · recruiting
Other Qifu Li trials
Trials by the same sponsor.
- NCT06941116 — Steroids-Based Screening for Primary Aldosteronism · recruiting
- NCT06635993 — Accuracy of 68Ga-Pentixafor PET/CT for Subtypting Diagnosis in Patients With Primary Aldosteronism Concurrent With Auton · recruiting
- NCT06833437 — 68Ga-Pentixafor PET/CT Versus Adrenal Vein Sampling in Diagnosing Unilateral Subtype of Primary Aldosteronism Concurrent · NA · recruiting
- NCT06457074 — Finerenone for Patients With Primary Aldosteronism (FAIRY) · Phase 4 · recruiting
- NCT06238232 — Outcome of 68Ga-Pentixafor PET/CT Versus Adrenal Vein Sampling in Primary Aldosteronism · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06955286 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Qifu Li
- Last refreshed: 1 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06955286.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing